LifeMD (LFMD) Projected to Post Earnings on Monday

LifeMD (NASDAQ:LFMD) is anticipated to release its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect LifeMD to announce earnings of ($0.14) per share and revenue of $48.80 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.01). LifeMD had a negative return on equity of 168.23% and a net margin of 0.10%. The business had revenue of $47.28 million during the quarter, compared to analysts’ expectations of $49.16 million. On average, analysts expect LifeMD to post ($0.48) EPS for the current fiscal year and ($0.06) EPS for the next fiscal year.

LifeMD Trading Up 1.4%

Shares of NASDAQ:LFMD traded up $0.03 on Monday, reaching $2.32. The company had a trading volume of 24,761 shares, compared to its average volume of 995,807. The firm has a market capitalization of $111.97 million, a PE ratio of -46.09 and a beta of 2.19. LifeMD has a 52-week low of $2.06 and a 52-week high of $5.96. The firm’s 50 day simple moving average is $2.81 and its 200-day simple moving average is $3.65.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. KeyCorp set a $5.00 price objective on shares of LifeMD and gave the stock an “overweight” rating in a research report on Friday, August 7th. Zacks Research upgraded shares of LifeMD from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th. Mizuho set a $7.00 target price on LifeMD in a research report on Thursday, August 6th. Wall Street Zen downgraded shares of LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of LifeMD in a research report on Thursday, September 17th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.57.

LifeMD Company Profile

LifeMD, Inc is a direct-to-consumer telehealth company that provides virtual medical care, prescription treatments and related health services through its digital platform. The company connects patients with licensed health care providers for online consultations, ongoing care and, when clinically appropriate, prescription medications.

Its services include virtual primary care and programs focused on areas such as weight management, men’s health, women’s health, dermatology and chronic-care support.